Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) Receives Consensus Rating of “Hold” from Analysts

Shares of Entasis Therapeutics Holdings Inc. (NASDAQ:ETTXGet Rating) have earned a consensus rating of “Hold” from the six research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $3.53.

Several research analysts recently commented on ETTX shares. Cantor Fitzgerald downgraded shares of Entasis Therapeutics from an “overweight” rating to a “neutral” rating in a report on Friday. Alliance Global Partners lowered shares of Entasis Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, March 16th. Zacks Investment Research lowered shares of Entasis Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. Wedbush lowered shares of Entasis Therapeutics from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $9.00 to $1.80 in a research report on Tuesday, March 8th. Finally, HC Wainwright downgraded shares of Entasis Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the company from $6.00 to $1.80 in a report on Friday, March 4th.

Shares of ETTX opened at $1.89 on Friday. The company has a market capitalization of $90.44 million, a PE ratio of -1.69 and a beta of 1.45. Entasis Therapeutics has a one year low of $1.40 and a one year high of $3.88. The company’s fifty day moving average price is $1.84 and its 200 day moving average price is $2.12.

Entasis Therapeutics (NASDAQ:ETTXGet Rating) last announced its earnings results on Wednesday, April 27th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.12). As a group, equities research analysts forecast that Entasis Therapeutics will post -1.2 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in ETTX. Geode Capital Management LLC raised its stake in shares of Entasis Therapeutics by 14.9% in the third quarter. Geode Capital Management LLC now owns 93,168 shares of the company’s stock worth $311,000 after acquiring an additional 12,047 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Entasis Therapeutics in the third quarter worth about $87,000. Two Sigma Investments LP raised its stake in shares of Entasis Therapeutics by 13.4% during the third quarter. Two Sigma Investments LP now owns 186,230 shares of the company’s stock worth $622,000 after buying an additional 22,001 shares during the last quarter. Two Sigma Advisers LP raised its stake in shares of Entasis Therapeutics by 40.5% during the third quarter. Two Sigma Advisers LP now owns 229,000 shares of the company’s stock worth $765,000 after buying an additional 66,058 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Entasis Therapeutics during the third quarter worth approximately $107,000. 6.91% of the stock is owned by institutional investors.

About Entasis Therapeutics (Get Rating)

Entasis Therapeutics Holdings Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii.

Recommended Stories

Analyst Recommendations for Entasis Therapeutics (NASDAQ:ETTX)

Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.